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Abstract
Purpose—Epidermal growth factor receptor family members (e.g., EGFR, HER2, HER3, and
HER4) are commonly overexpressed in pancreatic cancer. We investigated the effects of inhibition
of EGFR/HER2 signaling on pancreatic cancer to elucidate the role(s) of EGFR/HER2 in
radiosensitization and to provide evidence in support of further clinical investigations.
Experimental Design—Expression of EGFR family members in pancreatic cancer lines was
assessed by qRT-PCR. Cell growth inhibition was determined by MTS assay. The effects of inhibition
of EGFR family receptors and downstream signaling pathways on in vitro radiosensitivity were
evaluated using clonogenic assays. Growth delay was used to evaluate the effects of nelfinavir on
in vivo tumor radiosensitivity.
Results—Lapatinib inhibited cell growth in four pancreatic cancer cell lines, but radiosensitized
only wild-type K-ras-expressing T3M4 cells. Akt activation was blocked in a wild-type K-ras cell
line, whereas constitutive phosphorylation of Akt and ERK was seen in lines expressing mutant K-
ras. Overexpression of constitutively-active K-ras(G12V) abrogated lapatinib-mediated inhibition
of both Akt phosphorylation and radiosensitization. Inhibition of MEK/ERK signaling with U0126
had no effect on radiosensitization, whereas inhibition of activated Akt with LY294002
(enhancement ratio 1.2–1.8) or nelfinavir (enhancement ratio 1.2–1.4) radiosensitized cells
regardless of K-ras mutation status. Oral nelfinavir administration to mice bearing mutant K-ras-
containing Capan-2 xenografts resulted in a greater than additive increase in radiation-mediated
tumor growth delay (synergy assessment ratio of 1.5).
Conclusions—Inhibition of EGFR/HER2 enhances radiosensitivity in wild-type K-ras pancreatic
cancer. Nelfinavir, and other PI3K/Akt inhibitors, are effective pancreatic radiosensitizers regardless
of K-ras mutation status.
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Translational Relevance
In this article we provide two important pieces of evidence to guide future cancer care. First,
constitutive activation of K-ras results in resistance to radiosensitization by inhibition of
EGFR and HER2. This result suggests that use of EGFR/HER2 inhibitors as radiosensitizers
of pancreatic cancer may not be efficacious given the high K-ras mutation prevalence in
pancreatic cancer. Second, we provide the first evidence documenting the in vitro and in
vivo efficacy of nelfinavir as a radiosensitizer of pancreatic cancer and further evidence
supporting its role as a radiosensitizer. These results provide a rationale for future clinical
investigation of the tolerability and therapeutic efficacy of nelfinavir in combination with
radiotherapy in pancreatic cancer.
INTRODUCTION
Pancreatic cancer, with nearly 33,000 cases diagnosed annually, is the 4th leading cause of
cancer deaths in the United States (1). Improvements in understanding the molecular
aberrations underlying pancreatic cancer (reviewed in (2)), have led to the approval of drugs
targeting these abnormalities (3). Some of these agents target the members of the epidermal
growth factor receptor family (EGFR/ErbB-1/HER1, ErbB-2/HER2/neu, ErbB-3/HER3, and
ErbB-4/HER4).
Ligand activation of EGFR-family proteins (EGFR is a member of the receptor tyrosine kinase
superfamily of transmembrane proteins) results in perturbation of a variety of downstream
signaling cascades. The clinical efficacy of drugs targeting the EGFR family of proteins was
hypothesized due to the observed overexpression of EGFR in 40-70% of pancreatic cancers
(4,5), along with overexpression of HER2 in a smaller subset of cases (6-8). The use of EGFR
family inhibitors has been supported by data demonstrating that blockade of EGFR or HER2
inhibits the growth of pancreatic cancer cells in vitro (9-11). Downregulation of both EGFR
and HER2 has been suggested to be more effective at inhibiting pancreatic cancer cell
proliferation than inhibition of either receptor alone (12).
EGFR-family inhibitors have recently been demonstrated to radiosensitize multiple cancers
(reviewed in (13)). We have previously demonstrated that lapatinib (GW572016, Tykerb®,
GlaxoSmithKline), a dual EGFR and HER2 small molecule inhibitor, is an effective
radiosensitizer for breast cancer, a cancer that frequently expresses high levels of HER2 and/
or EGFR (14). Interestingly, the signaling pathway(s) downstream of EGFR/HER2 responsible
for radiosensitization appears to vary by cancer subtype. While numerous compounds have
been used successfully in laboratory studies to directly inhibit signaling pathways located
downstream of EGFR and/or HER2, translation to efficacious and tolerable clinical use has
been difficult.
Nelfinavir (Viracept®, Pfizer), a Type 1 HIV protease inhibitor, may downregulate Akt
signaling with minimal side effects. HIV protease inhibitors were first noted to inhibit the
growth of Kaposi's sarcoma independent of their anti-retroviral effect soon after receiving FDA
approval in 1997 (15,16). Several groups then showed that these compounds radiosensitize
several tumor cells via blockade of Akt signaling (17) and/or proteasome inhibition (18). The
exact mechanism of this effect remains unclear, as nelfinavir has been demonstrated to increase
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caspase-dependent apoptosis, non-apoptotic (caspase-independent) death, endoplasmic
reticulum stress, and autophagy (19,20).
We initiated this study to determine whether inhibition of EGFR/HER2 signaling could
sensitize pancreatic cancer to ionizing radiation to provide data in support of a clinical trial.
We expanded the study to determine the downstream signaling pathways involved in
radiosensitization and to demonstrate that nelfinavir, and other agents that inhibit the
PI3K→Akt pathway, is an effective radiosensitizer in the majority of pancreatic cancers.
MATERIALS AND METHODS
Inhibitors and growth factors
Lapatinib (Tykerb®) was provided by GlaxoSmithKline (Middlesex, United Kingdom).
LY294002 was obtained from Sigma Chemical Co. (St. Louis, MO) and U0126 from
Calbiochem (La Jolla, CA). Inhibitors were reconstituted in DMSO and working solutions
subdivided and stored at −20 °C. Tablets of nelfinavir mesylate (650 mg) were purchased from
the UNC inpatient pharmacy and ground into fine powder before being dissolved into 100%
ethanol prior to each use. EGF ligand was obtained from Invitrogen (Carlsbad, CA). Control
cells were treated with equal concentrations of DMSO or ethanol.
Quantitative reverse transcription-PCR (qRT-PCR)
Gene-specific 5’-3’ oligonucleotides and intervening fluorescent dye-labeled probes for human
genes encoding EGFR, HER2, HER3, and HER4 (Supplemental Table 1) were designed,
synthesized, labeled, and purified using standard techniques. Real-time fluorescence
quantitative PCR (qPCR) was performed with an ABI PRISM 7900 instrument from Applied
Biosystems (Foster City, CA). mRNA sequences for each gene were transcribed in vitro using
MEGAscript (Ambion, Austin, TX), and used as positive controls and absolute quantitation
standards for the assays. Amplification of two-fold serial dilutions of RNA was used to
construct standard linear curves that permitted accurate measurements of 200 to 90 million
template copies. Total RNA was isolated from each cell line in triplicate by using a QIAGEN
(Valencia, CA) RNeasy kit and was treated with RNase-free DNase. Total RNA (10 ng) isolated
from each cell line was assayed.
Cell lines and culture conditions
Pancreatic cancer cell lines (T3M4, Capan-2, MIA PaCa-2, and PANC-1) were obtained from
the American Type Culture Collection (ATCC) and cultured in RPMI-1640 supplemented with
10% FBS, penicillin (100 units/ml), and streptomycin (100 mg/ml). No additional
authentication was performed although the ATCC performs DNA profiling of cell lines and
all cell lines were cultured for less than 6 months prior to being reconstituted from frozen
stocks. Cells were maintained as monolayer cultures at 37°C in a humidified atmosphere of
5% CO2.
Cell proliferation assay and IC50 determination
Cells (1.5-5 × 103 cells/well) were plated on 96 well plates in 100 μl media with increasing
concentrations of lapatinib (0.01 μM to 50.0 μM) or nelfinavir (0.001 μM to 20.0 μM). After
72 h, cell viability was measured via MTS assay according to the manufacturer's directions
(Promega, Madison, WI). IC50 values and 95% confidence intervals were calculated according
to a non-linear curve fit and compared by the extra sum-of-squares F test using GraphPad Prism
version 5.01 (GraphPad Software, San Diego, CA).
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Immunoprecipitation and western blot analysis
Cells were initially starved overnight followed by 1 h lapatinib (1 or 5 μM) pretreatment and
then EGF (10 ng/ml) stimulation for 15 min. Cellular extracts were prepared by washing cells
with cold phosphate-buffered saline (PBS) and lysing them in cold NLB buffer (20 mM HEPES
[pH 7.3], 50 mM sodium fluoride, 10% glycerol, 1% Triton X-100, 5 mM EDTA, 0.5 M NaCl,
1 mM sodium vanadate, aprotinin [6 μg/ml], and leupeptin [10 μg/ml]). Receptor proteins were
precipitated from cell lysates (1 mg) with a commercial antibody against HER2 (clone 9G6.10;
Neomarkers, Inc./Thermo Scientific, Fremont, CA) or with a non-commercial antibody against
HER1/EGFR (V22) kindly provided by S. Earp (Univ. of North Carolina) (14) at 4°C overnight.
Immunocomplexes were then pulled down with protein A/G-agarose beads (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) for 3 h at 4°C, washed three times with NLB, and
analyzed by western blot analysis using an anti-phosphotyrosine antibody (PY20-HRP; Santa
Cruz Biotechnology, Inc).
Western blot analyses were performed to determine the effect of pharmacological inhibitors
on MEK/ERK1/2 and PI3K/Akt activation. Cells were plated at 40% confluence in 60 mm
dishes and the following day treated with inhibitors against EGFR/HER2 (lapatinib, 1-5 μM),
PI3K (LY294002, 5-20 μM), MEK1/2 (U0126, 1-5 μM), or vehicle alone (DMSO) for one
hour or with nelfinavir (1 μM) or vehicle alone (ethanol) for 4 or 28 h prior to lysis. Thirty
μg of protein lysates (harvested as described above) were separated over 15% SDS-PAGE gels,
transferred to Immobilon-P membrane (Millipore, Billerica, MA) and immunoblots performed
utilizing phospho-ERK1/2- (#9106), ERK1/2- (#9122), phospho-Akt(Ser473)- (#9271), or
Akt-(#9272), specific antibodies (all from Cell Signaling Technology, Inc., Cambridge, MA).
Anti α-tubulin (TU-02) was obtained from Santa Cruz Biotechnology.
Clonogenic survival assays
Cells were trypsinized to create single cell suspensions, seeded into T-25 flasks at defined
densities, and incubated overnight to ensure log phase of growth. The next day, two hours pre-
irradiation, cells were fed with fresh media supplemented with either lapatinib (5 μM), U0126
(5 μM), or LY294002 (10 μM). Cells treated with nelfinavir (1 or 5 μM) received 2 or 26 h of
pre-treatment prior to irradiation. Control cells were maintained in media containing a
corresponding concentration of vehicle (DMSO or ethanol) alone. Cells were irradiated with
single doses of 1, 3, 5, or 7 Gy using a Mark I 137Cs irradiator (JL Shepherd, San Fernando,
CA) delivering a dose rate of 158 cGy/min. Two hours post-irradiation, all drugs were removed
and the cells re-fed with fresh media. After 10 to 15 days, surviving colonies were fixed with
a solution of methanol and acetic acid (3:1 v/v) and stained with 1% crystal violet. Colonies
containing more than 50 cells were counted and survival curves were generated.
The surviving fraction was calculated from the number of colonies formed in the irradiated
dishes compared with the number formed in the unirradiated control, where plating efficiency
is defined as the percentage of cells plated that form colonies in unirradiated dishes, and
surviving fraction = number of colonies formed/(number of cells plated × plating efficiency).
Statistical comparisons were done using GraphPad Prism according to the two-tailed
nonparametric Mann-Whitney test. The clonogenic survival curve for each condition was fitted
to a linear-quadratic model (Y=e−[A * X + B * X2]) using GraphPad Prism according to a least
squares fit, weighted to minimize the relative distances squared, and compared using the extra
sum-of-squares F test. Each point represents the mean surviving fraction calculated from three
independent experiments done in triplicate for each treatment condition; error bars represent
the standard deviation. The mean inactivation dose was calculated according to the method of
Fertil (21) and the cell survival enhancement ratio (ER) was calculated as the ratio of the mean
inactivation dose under control conditions divided by the mean inactivation dose after drug
exposure as described by Morgan (22). A value significantly greater than 1 indicates
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radiosensitization. For the drug dose response comparison, two-way ANOVA followed by
Bonferroni posttests was performed using GraphPad Prism.
Ectopic expression of mutant K-ras
T3M4 cells, which are wild-type for K-ras, were transfected with pCGN-K-ras(G12V)-HA or
an empty vector control as previously described (23) using FuGENE 6 Transfection Reagent
(Roche Diagnostics, Indianapolis, IN). Clonogenic survival assays were performed 24 hours
after transfection and protein lysates prepared as described above for western blot analysis with
anti-K-ras serum (#OP24; Calbiochem, San Diego, CA).
Xenografts
Four to five week-old athymic BALB/c female nude mice were purchased from Charles River
Laboratories (Wilmington, MA), housed in filter-topped cages in an aseptic environment, and
maintained per defined protocol approved by and in accordance with the University of North
Carolina Institutional Animal Care and Use Committee. To determine the biologically optimal
dose of nelfinavir with regards to inhibition of Akt activation, mice (n=1 per group) were
injected subcutaneously in the flanks with Capan-2 cells (5 × 106) resuspended in 200 μl of a
1:1 ratio of PBS:Matrigel (BD Biosciences, San Jose, CA) and treated with nelfinavir (50, 100,
or 150 mg/kg once daily) or vehicle alone by oral gavage for a total of five days. Mice were
euthanized by CO2 inhalation and tumors harvested using sterile technique 4 hours after the
last dose on day 5. Excised tumors were flash frozen and pulverized with a mortar and pestle
under liquid nitrogen prior to transfer into 1-2 ml of RIPA buffer [150 mM NaCl, 50 mM Tris-
HCl pH 7.5, 0.25% deoxycholate, 1% NP-40, 1 mM sodium orthovanadate, and complete
protease inhibitor cocktail (Roche Applied Science, Indianopolis, IN)]. Lysates were then
homogenized using a Polytron homogenizer (Brinkmann, Westbury, NY), incubated on ice for
30 min, and centrifuged at 14,000 rpm at 4°C for 15 minutes; supernatants were stored at −80°
C prior to immunoblotting for P-Akt, Akt, and α-tubulin as described above.
To assess the tumor growth delay induced by nelfinavir, mice (n=6 per group) bearing Capan-2
xenografts prepared as described above were randomly assigned to one of four treatment
groups: 1) vehicle alone, 2) nelfinavir alone (150 mg/kg daily by oral gavage) × 10 days, 3)
radiation alone (200 cGy/day on days 6, 7, and 8), or 4) radiation plus nelfinavir (as above).
Radiation was delivered by a linear accelerator (Primus, Siemens, New York, NY) to
anaesthetized mice using 6 MeV electrons and a custom lead cutout. Tumors were measured
at 2-3 day intervals using Vernier calipers and the tumor volumes calculated (V = π × length
× width2 / 6). Tumor volumes were fit using a straight line non-linear regression (GraphPad
Prism) and compared using the extra sum-of-squares F test.
To assess antagonistic, additive, or synergistic effects, we used the fractional product method
at day 25 (24,25). The observed fractional tumor volume (FTV) is equal to the mean tumor
volume of each treated group (nelfinavir, radiation, or nelfinavir + radiation) divided by the
mean tumor volume of the control group. The expected FTV from the combined treatment
(FTVnelfinavir + radiation) is calculated by multiplying the observed FTVnelfinavir by the observed
FTVradiation. Dividing the expected FTVnelfinavir + radiation by the observed
FTVnelfinavir + radiation yields a synergy assessment ratio in which a value >1 suggests that the
combined treatments are effectively synergistic, <1 antagonistic, and =1 additive.
RESULTS
Lapatinib blocks EGFR and HER2 activation
We have shown previously that both lapatinib and erlotinib, an EGFR-selective tyrosine kinase
inhibitor, block the soft-agar growth of several pancreatic cancer cell lines1. Since EGFR
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inhibition has been demonstrated to radiosensitize other cancers, including head and neck
squamous cell carcinomas (HNSCC) and breast cancer (13), we sought to determine whether
these compounds could also radiosensitize pancreatic cancer cells and whether this
radiosensitization correlated with EGFR and HER2 expression.
We first evaluated by qRT-PCR the relative expression levels of all four members of the EGFR
family of receptors among a panel of four pancreatic cancer cell lines (Table 1). While HER2
levels were similar among all four lines, EGFR levels were 10-17-fold higher in the PANC-1
and T3M4 cells relative to that observed in the Capan-2 and MIA PaCa-2 cells. Expression of
HER3, a family member that lacks kinase activity, was approximately 10-fold higher in the
Capan-2 and T3M4 cells. HER4, the final family member, had very low mRNA expression
levels across all four cell lines.
All cell lines showed an anti-proliferative effect in response to increasing concentrations of
both erlotinib and lapatinib (Table 1). The dual EGFR/HER2 inhibitor lapatinib demonstrated
improved growth inhibitory activity compared to erlotinib in Capan-2 and MIA PaCa-2 cell
lines (p = 0.0008 and 0.0001, respectively), a finding consistent with low levels of EGFR
mRNA in these cell lines. PANC-1 and T3M4 cells had higher levels of EGFR than HER2
expression, and demonstrated similar growth inhibition by lapatinib and erlotinib (p=ns). To
demonstrate that lapatinib blocks ligand-stimulated EGFR and HER2 activation in our
pancreatic cells activation of receptors was analyzed by immunoprecipitation followed by
western blot analysis. Consistent with what we and others have previously reported using in
vitro, in vivo, and patient samples ((14,26)and reviewed in (27)), lapatinib blocked activation
of both EGFR and HER2 in all four pancreatic cell lines (Fig. 1A).
Pancreatic cancer cell lines harboring K-ras mutations are resistant to lapatinib-mediated
radiosensitization
Due to the improved anti-proliferative and ligand-stimulated receptor inhibition of lapatinib
in the tested cell lines, we chose to investigate whether lapatinib could radiosensitize pancreatic
cancer cells. Clonogenic survival assays were performed on our panel of cells that were either
treated with lapatinib (5 μM) or vehicle alone for the 2 hours preceding and 2 hours after
irradiation. We chose this short duration of drug treatment because the clonogenic survival and
cell cycle distribution of non-irradiated cell lines that were pretreated in this fashion with either
lapatinib or DMSO control were not statistically different (data not shown), suggesting that
the 4 hour exposure to lapatinib did not radiosensitize cells simply by inhibiting proliferation
or by redistributing cells to a more radiosensitive phase of the cell cycle. T3M4 cells were
radiosensitized by lapatinib while MIA PaCa-2, PANC-1, and Capan-2 cells were not
radiosensitized (Fig. 1B). Lapatinib-mediated radiosensitization occurred in a dose-dependent
manner (Supplemental Fig. 1) and at doses unlikely to have significant off-target effects (28).
The ER of 1.3 for T3M4 cells is consistent with that reported for known radiosensitizers such
as gemcitabine or cisplatin (29,30). Suggestive of the importance of K-ras mutations in the
radiation response, T3M4 cells express wild-type K-ras while MIA PaCa-2, PANC-1 and
Capan-2 cell lines all express mutant K-ras (31).
The presence of constitutively active, mutant forms of K-ras, a molecular abnormality seen in
approximately 90% of pancreatic cancers (32,33), has previously been demonstrated to confer
radioresistance (34-37). Thus, we hypothesized that inhibition of EGFR/HER2 signaling by
lapatinib with resulting radiosensitization was conferred through inhibition of specific
downstream signaling pathways that are directly activated in the presence of constitutively
1Baerman K, Caskey L, Sasi F, Earp H, Calvo B. EGFR/HER2 targeted therapy inhibits growth of pancreatic cancer cells. 2005
Gastrointestinal Cancers Symposium; 2005. p. Abst 84.
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active Ras. We first evaluated the ability of lapatinib to inhibit downstream signaling of the
PI3K/Akt and Raf/MEK/ERK pathways, two pathways capable of being activated by both
EGFR/HER2 and Ras. Activation of Akt, but not ERK1/2, was completely inhibited by
lapatinib in the T3M4 cells, while neither ERK1/2 nor Akt were inhibited by lapatinib in cells
with mutant K-ras (Fig. 1C). Taken together, these data suggest that resistance to lapatinib
radiosensensitization in the MIA PaCa-2, PANC-1, and Capan-2 cells may be mediated by
activation of PI3K/Akt by mutant Ras.
K-ras expression blocks radiosensitization by lapatinib
To determine the role of mutant Ras in conferring radioresistance in these cells, we next
evaluated whether ectopic expression of mutant K-ras could abrogate lapatinib-mediated
radiosensitization of T3M4 cells. Cells treated with lapatinib that were expressing K-ras
(G12V), but not vector control, exhibited sustained Akt activation and no change in ERK
activation (Fig. 2A). This correlated with a lack of radiosensitization by lapatinib in cells
expressing K-ras(G12V), but not vector control (Fig. 2B). These results support a model in
which the presence of mutant K-ras can render pancreatic cancer cells resistant to lapatinib-
mediated radiosensitization.
Pancreatic cancer cells are radiosensitized by inhibition of PI3K/Akt, but not MEK/ERK
If activated Ras could block the radiosensitization observed with lapatinib-mediated inhibition
of EGFR/HER2 in the T3M4 cells, we reasoned that radiosensitization by lapatinib was being
mediated by the inhibition of a downstream signaling pathway(s) that is activated by both
EGFR/HER2 and Ras. In addition, we hypothesized that in the mutant K-ras cell lines (MIA
PaCa-2, PANC-1, and Capan-2) activation of these downstream pathways by Ras could be
responsible for their observed resistance to lapatinib-mediated radiosensitization. Downstream
signaling from EGFR/HER2 and Ras are both known to activate several key pathways in
common, including the Raf/MEK/ERK and PI3K/Akt pathways (13,38). To determine whether
inhibition of Raf/MEK/ERK and/or PI3K/Akt could radiosensitize pancreatic cancer cells, we
evaluated the ability of U0126, a MEK inhibitor and known breast cancer radiosensitizer
(14), and LY294002, a PI3K inhibitor (39), to sensitize our panel of pancreatic cancer cell lines
to radiation-induced cell death. Despite effective inhibition of ERK1/2 phosphorylation in all
cell lines by U0126 (Supplemental Fig. 2A), this inhibition of MEK/ERK activation did not
radiosensitize any of the pancreatic cancer cell lines (Supplemental Fig. 2B). A modest increase
in Akt activation was seen in some cell lines in response to U0126 treatment, a result consistent
with feedback-signaling loops described by others (40,41) and consistent with the role of Akt
in the radiation response. In contrast, treatment with LY294002 resulted in effective inhibition
of Akt with consequent radiosensitization (ERs ranged from 1.3 to 2.1) of all cells regardless
of their K-ras mutational status (Figs. 3A, B).
Nelfinavir blocks Akt phosphorylation and radiosensitizes both wild-type and mutant K-ras
cell lines
Several FDA approved HIV protease inhibitors including nelfinavir and ritonivir have been
shown to block Akt signaling and radiosensitize HNSCC, breast, lung, and brain tumor cell
lines (19,42-46). Since currently available PI3K inhibitors have demonstrated unacceptable
clinical toxicity, we sought to evaluate whether inhibition of the PI3K/Akt pathway with
nelfinavir would radiosensitize pancreatic cancer cells. Cells treated with a clinically attainable
dose of nelfinavir (47) or vehicle alone showed decreased Akt activation after 28 hours, but
not after a four hour exposure (Fig. 4A). Little change in ERK1/2 activation (Fig. 4A) or cell
cycle distribution (data not shown) was seen at either time point.
To determine the effect of nelfinavir on radiation response, cells were similarly pretreated with
nelfinavir for either 2 or 26 hours prior to and 2 hours after irradiation and their ability to
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proliferate in clonogenic survival assays determined. Both mutant and wild-type K-ras cells
were radiosensitized (ERs ranged from 1.3 to 1.5, Fig. 4B) after 26 hours of nelfinavir pre-
treatment. Consistent with effects on Akt activation, no radiosensitization was seen after 2 hour
pre-treatment. To exclude the possibility that nelfinavir treatment induces growth arrest, MTS
assay was used to monitor proliferation after exposure to nelfinavir for either 2 or 26 hours.
No significant difference in proliferation was seen with either length of exposure in any of the
four cell lines tested (data not shown).
Nelfinavir inhibits Akt activation and results in tumor growth delay of Capan-2-bearing
xenografts
We next assessed the ability of nelfinavir to radiosensitize a mouse xenograft model utilizing
Capan-2 cells, chosen based on their robust ability to form tumors. First, to determine the
optimal dose of nelfinavir required to inhibit Akt activation in vivo, Capan-2 cells (5 × 106)
were injected into the flanks of athymic BALB/c nude mice. After palpable tumors developed,
mice were treated with indicated doses of nelfinavir or vehicle control by gastric gavage for 5
consecutive days. On the 5th day, mice were sacrificed, tumor lysates prepared, and Akt
activation assessed by western blot analysis. At a dose of 150 mg/kg, phospho-Akt levels in
vivo were significantly decreased (Fig. 5A). With this optimized dose, tumor growth in cohorts
(n=6 mice per treatment group) were compared with mice either sham-treated or treated with
nelfinavir, radiation, or nelfinavir plus radiation. A clinically relevant dose of radiation (2 Gy
per fraction) was chosen to provide meaningful assessment of any radiosensitization. Tumor
growth following treatment was significantly slower in mice treated with nelfinavir and
radiation than with either treatment alone (Fig. 5B, p<0.0001) and was consistent with synergy
between radiation and nelfinavir as demonstrated by a synergy assessment ratio (± SEM) of
1.5 ± 0.27 as determined by the fractional product method (Fig. 5C). In addition, the slopes of
the tumor volume curves after completion of all treatments (day 10) differed significantly (p=<.
0001) consistent with synergy between radiation and nelfinavir. Consistent with the survival
of some tumor cells after the initial treatment, a repopulation with similar growth rates was
observed after day 20. However, tumor volumes in the nelfinavir plus radiation treatment were
consistently significantly reduced in comparison to controls consistent with synergy between
radiation and nelfinavir. Collectively, these data support a model in which blockade of an
activated PI3K/Akt pro-survival pathway mediates radiation sensitization and provides
evidence that drugs such as nelfinavir or other novel agents targeting this pathway may be
efficacious radiosensitizers worthy of further study.
DISCUSSION
EGFR and/or HER2 are overexpressed in a significant number of pancreatic cancers (4-8) and
blockade of EGFR or HER2 inhibits the growth of pancreatic cancer cells in vitro (9-11).
Erlotinib has been approved for the treatment of pancreatic cancer (3) and its role as a
radiosensitizer is currently being studied in clinical trials. Due to the growing evidence
supporting the ability of pharmacological inhibitors of EGFR and HER2 to radiosensitize
multiple types of cancers including breast, HNSCC, colon, and pancreas [reviewed in (13)],
and due to overexpression of both EGFR and HER2 in pancreatic cancer, we hypothesized that
dual inhibition of EGFR and HER2 with lapatinib would sensitize pancreatic cancer to
radiation.
In our preliminary studies, we sought to determine whether inhibition of both EGFR and HER2
with lapatinib would be superior to inhibition of EGFR alone with erlotinib. As expected,
lapatinib had an improved proliferative IC50 in cell lines with high HER2 mRNA levels and
had a similar IC50 as erlotinib in cells with high levels of EGFR mRNA. Thus, we chose to
study the ability of lapatinib to radiosensitize pancreatic cancer. Intriguingly, we found that
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lapatinib was an effective radiosensitizer in only the T3M4 line that did not harbor a mutant
form of K-ras despite its ability to block EGFR and HER2 activation (Fig. 1A), cellular
proliferation (Table 1), and soft agar growth (B. Calvo, unpublished data) in multiple cell lines.
This was consistent with the results reported recently by Morgan et al. in which erlotinib
radiosensitized a single cell line expressing wild-type K-ras (22). Due to the expression of
mutated K-ras in >90% of pancreatic cancers (32,33), our data suggests that targeting EGFR
and HER2 in a clinical trial is unlikely to be a successful strategy for radiosensitization of
pancreatic cancer. Given the wealth of evidence supporting resistance of K-ras mutated cancers
to EGFR targeted therapies [reviewed in (48)], this finding is not surprising.
The differential effect of lapatinib on growth inhibition and radiosensitization adds to evidence
that the downstream signaling pathways responsible for these biological responses can be
uncoupled. We have previously shown that ERK inhibition correlates with both growth
inhibition and radiosensitization in EGFR overexpressing breast cancer cell lines (14) while
HER2 overexpressing breast cancer cell lines show growth delay but not radiosensitization in
response to therapies that inhibit Akt (manuscript in preparation). These differences may
depend upon alternative activation of intracellular feedback loops via collateral pathway
activation, a mechanism of resistance to tyrosine kinase inhibitors recently described by several
groups (40,41).
We have shown that lapatinib decreased Akt-activation in T3M4 cells and that overexpression
of activated K-ras in these cells abrogated the ability of lapatinib to both inhibit Akt and
radiosensitize these cells. Direct inhibition of the PI3K/Akt pathway radiosensitized all cells
independent of their K-ras mutational status while inhibition of MER/ERK signaling had no
effect on the radiation sensitivity of any cell line tested. These results add support to the growing
body of evidence that the PI3K/Akt signaling pathway plays a vital role in radiosensitization
(17,34,42,49-52) and provides further evidence that Akt inhibitors may be promising clinical
radiosensitizers.
Finally, we show that nelfinavir, an HIV protease inhibitor blocked Akt activation and
radiosensitized both wild-type and mutant K-ras containing cells at concentrations attainable
in humans (47). The radiation enhancement ratio of nelfinavir ranged from 1.2 to 1.4, values
that can result in a large cumulative effect when applied over many daily fractions of radiation
(Fig. 5D). Using a xenograft system, we demonstrated that oral nelfinavir decreased intra-
tumor Akt activation in vivo and synergized with clinically relevant fractionated radiation
doses. The exact mechanism of action of nelfinavir remains unclear. In addition, whether all
HIV protease inhibitors share a common mechanism of radiosensitization remains untested.
Saquinavir, a compound in the class of HIV protease inhibitors has been shown to block
proteasome function stabilizing IκB, and decreasing NFκB in glioblastoma and prostate cancer
cell lines (18). Others have pointed to a role of the ER stress response and/or the unfolded
protein response resulting in phosphatase activation and Akt dephosphorylation in a head and
neck squamous cell carcinoma cell line (44). Both decreased Akt and NFκB activation can
contribute to radiosensitization. In addition, HIV protease inhibitors may enhance tumor
oxygenation through inhibition of HIF-1 and VEGF as demonstrated in glioblastoma, lung
carcinoma, and head and neck squamous cell carcinoma cell lines, thus rendering tumors more
sensitive to radiation regardless of effects on intracellular signaling pathways (43,45). The
potential cell line specific differences in mechanism highlight the importance of studying
potential treatments in multiple systems.
These results provide valuable information in support of the use of nelfinavir as a clinically
relevant radiosensitizer for pancreatic cancer. While a small phase I trial combining radiation
and nelfinavir with increasing doses of gemcitabine has recently been completed (53) this trial
was not designed to determine the biologically effective dose of nelfinavir. In addition, the
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tolerability of adding nelfinavir, or other novel Akt inhibitors, to radiation and 5-fluorouracil
or capecitabine, a common regimen used in the treatment of pancreatic cancer deserves further
study.
While we have delineated the PI3K/Akt pathway as an important component of radiation
sensitization in pancreatic cancer, other signaling pathways downstream of EGFR/HER2, Ras
or yet undefined signaling node proteins may also play an important role in this response. It is
also possible that the off target effects may play a role in radiosensitization. Several groups
have shown that LY294002 inhibits not only PI3K, but at concentrations higher than used in
our studies can also inhibit PI3K-like kinases such as DNA-PK, a key regulator of DNA double
strand break repair (54,55). The concomitant use of multiple targeted therapies is being
investigated in our lab and others and may result in improved tumor control both locally and
distantly. Care must be used in these cases, as drug combinations may result in unexpected
therapeutic antagonism, have increased toxicities, and lead to unexpected clinical
consequences. While the treatment of metastatic disease remains of critical importance in the
treatment of pancreatic cancer, a substantial portion of patients are still dying of local disease,
underlying the importance of both improved local and systemic therapies (56).
CONCLUSION
We have provided evidence that the high incidence of K-ras mutations in pancreatic cancer
makes the use of EGFR and/or HER2 inhibitors as radiosensitizers in this disease unlikely to
be efficacious. This is consistent with findings reported by several groups that mutations in K-
ras render non-small cell lung cancer and colorectal cancer resistant to EGFR-targeted therapy
(reviewed in (57)) and complements data provided by Morgan and colleagues that erlotinib is
a radiosensitizer for a wild-type K-ras-containing pancreatic cancer cell line (22). Furthermore,
we demonstrate that persistent activation of the PI3K/Akt pathway via constitutively active K-
ras correlates with a lack of radiosensitization and that direct inhibition of the PI3K/Akt
pathway results in radiosensitization regardless of K-ras mutational status. Most importantly,
nelfinavir, an HIV protease inhibitor, both decreases Akt phosphorylation and radiosensitizes
several pancreatic cancer cell lines regardless of K-ras mutation status. While most inhibitors
of the PI3K/Akt pathway are too toxic for routine clinical use, nelfinavir is routinely used long-
term for the treatment of HIV with relatively few side-effects. Additional studies into the
tolerability and efficacy of combined treatment with nelfinavir, traditional cytotoxic
chemotherapy, and radiation for the treatment of pancreatic cancer are warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. Lapatinib inhibits EGFR and HER2 but does not radiosensitize pancreatic cancer cells
A, Lapatinib inhibits EGF-induced activation of EGFR and HER2 in all four cell lines. Cells
were serum-starved and treated with lapatinib and/or EGF. Lysates were subjected to
immunoprecipitation with anti-EGFR or anti-HER2 antibodies and then immunoblotted with
an anti-phosphotyrosine antibody. B, T3M4 cells harvoring wild-type K-ras were
radiosensitized by lapatinib treatment (p<0.0001) whereas lines harboring mutant K-ras (MIA
PaCa-2, Capan-2, and PANC-1) were not radiosensitized by lapatinib. Plating efficiency of
unirradiated cells in the presence or absence of lapatinib was not significantly different for any
cell line. C, Lapatinib strongly inhibits constitutive phosphorylation of Akt in T3M4 cells
harboring wild-type K-ras whereas cells harboring K-ras mutations (Capan-2, MIA PaCa-2
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and PANC-1) show little/no inhibition of Akt phosphorylation. Cells were treated with
lapatinib at the indicated doses for 2 hours and protein lysates collected and analyzed by western
blot analysis with indicated antibodies.
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FIGURE 2. Ectopic expression of mutant K-ras abrogates lapatinib-mediated radiosensitization of
T3M4 cells
A, T3M4 cells were transfected with either empty vector (pCGN) or pCGN-K-ras(G12V)-HA,
subjected to treatment with lapatinib (5 μM) or DMSO vehicle for 2 hours and protein lysates
harvested and analyzed by western blot analysis with antibodies against p-ERK1/2, ERK1/2,
p-Akt or Akt. Expression of K-ras(G12V) blocked lapatinib-mediated Akt inhibition in T3M4
cells. B, Clonogenic survival assays of T3M4 cells transfected with pCGN vector control
showed radiosensitization by lapatinib (p<0.0001) whereas cells expressing pCGN-K-ras
(G12V)-HA were completely resistant to the radiosensitizing effect of lapatinib treatment.
Plating efficiency of unirradiated cells in the presence or absence of lapatinib was not
significantly different for any cell line.
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FIGURE 3. Pancreatic cancer cells are radiosensitized by inhibition of PI3K/Akt
A, Akt phosphorylation is inhibited by treatment with LY294002 (5, 10, or 20 μM) but not
DMSO control for 2 hours prior to collection of protein lysates and analysis by western blot.
B, In clonogenic survival assays, LY294002 (10 μM) radiosensitized all pancreatic cancer cell
lines tested, regardless of K-ras mutation status (p ≤ 0.002 for each). Plating efficiency of
unirradiated cells in the presence or absence of LY294002 was not significantly different for
any cell line.
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FIGURE 4. Nelfinavir inhibits Akt phosphorylation and radiosensitizes both wild-type and mutant
K-ras pancreatic cell lines
A, Cells were treated with nelfinavir (1 μM) for 4 or 28 h, and levels of p-ERK1/2 and p-Akt
assessed by western blotting as above. After 28 hours, phosphorylation of Akt, but not ERK1/2,
was decreased. B, All cell lines tested were radiosensitized following pretreatment with
nelfinavir (1 μM) for 26 hours prior to and 2 hours after radiation.
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FIGURE 5. Nelfinavir inhibits Akt phosphorylation and radiosensitizes Capan-2 xenografts
A, Capan-2 cells (5 × 106) were injected into the flank of nude mice and allowed to grow until
palpable, prior to initiating treatment with indicated doses of nelfinavir administered via gastric
gavage once daily. Mice were sacrificed on the 5th day of therapy and cellular lysates analyzed
by western blot for total-Akt, phospho-Akt, and α-tubulin. B, Mean tumor volumes (n=6 per
group). C, Fractional product values showing synergy for nelfinavir plus radiation treatment
with an observed:expected ratio of 1.5 ± 0.27 at day 25. D, Cumulative surviving fraction (CSF)
following multiple small doses of radiation alone (solid line) and radiation + nelfinavir (dotted
line). Based on the surviving fraction after 2 Gy (SF2Gy) for Capan-2 cells (Fig. 4B) treated
with radiation alone (SF2Gy = 0.85) or radiation + nelfinavir (SF2Gy = 0.68), where CSF =
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SF2Gy^(# of 2 Gy fractions) and using the assumptions of no repopulation, reoxygenation, or
redistribution and a constant SF2Gy over time.
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